GeneSystem Co

GeneSystem Co EPS Growth

The EPS Growth of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is -33.90 %. In the previous year, EPS Growth was -15.52 % — a change of 118.51% (lower).

EPS Growth

-33.90 %

YoY

118.51%

Last updated:

EPS Growth of GeneSystem Co is 2025 -33.90 % . EPS Growth of GeneSystem Co was 2024 -15.52 % . It decreases by 118.51% lower compared to the previous year.

The GeneSystem Co EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
-63.23 KRW
Jan 1, 2020
44.96 KRW
Jan 1, 2021
258.10 KRW
Jan 1, 2022
-351.45 KRW
Jan 1, 2023
12.70 KRW
Jan 1, 2024
-15.52 KRW
Jan 1, 2025
-33.90 KRW
The GeneSystem Co EPS Growth history
YEAREPS GrowthYoY
-33.90 %+118.51%
-15.52 %-222.13%
12.70 %-103.61%
-351.45 %-236.17%
258.10 %+474.04%
44.96 %-171.11%
-63.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

EPS Growth of GeneSystem Co is -33.90 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — GeneSystem Co

All Key Metrics — GeneSystem Co